EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.
暂无分享,去创建一个
G. Reifenberger | K. Shokat | M. Weller | N. Jura | W. Weiss | Justin Chen | Q. Fan | W. C. Gustafson | E. Charron | Jasmine Lau | Christiane B. Knobbe-Thomsen | P. Zipper | Robyn A. Wong | C. Knobbe-Thomsen | Christine K. Cheng | W. Gustafson
[1] N. St-Pierre,et al. Effects of transient changes in silage dry matter concentration on lactating dairy cows. , 2013, Journal of dairy science.
[2] C. Rock,et al. Perturbation of Staphylococcus aureus Gene Expression by the Enoyl-Acyl Carrier Protein Reductase Inhibitor AFN-1252 , 2013, Antimicrobial Agents and Chemotherapy.
[3] Steven J. M. Jones,et al. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma , 2013, Acta Neuropathologica.
[4] K. Aldape,et al. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. , 2012, Neuro-oncology.
[5] R. McLendon,et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. , 2011, Cancer cell.
[6] Raymond Sawaya,et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Yoshitaka Narita,et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.
[8] P. Birner,et al. STAT3 tyrosine phosphorylation influences survival in glioblastoma , 2010, Journal of Neuro-Oncology.
[9] F. Ali-Osman,et al. Cyclooxygenase-2 Is a Novel Transcriptional Target of the Nuclear EGFR-STAT3 and EGFRvIII-STAT3 Signaling Axes , 2010, Molecular Cancer Research.
[10] G. Reifenberger,et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] John Kuriyan,et al. Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.
[12] David S. Yang,et al. The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas , 2008, Clinical Cancer Research.
[13] G. Carpenter,et al. Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation , 2007, Proceedings of the National Academy of Sciences.
[14] K. Shokat,et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. , 2007, Cancer research.
[15] Chao Zhang,et al. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. , 2007, Nature chemical biology.
[16] A. Scott,et al. The Efficacy of Epidermal Growth Factor Receptor–Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization , 2007, Clinical Cancer Research.
[17] R. McLendon,et al. Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma , 2006, Clinical Cancer Research.
[18] Kimmo J Hatanpaa,et al. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. , 2006, Cancer research.
[19] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[20] David J. Yang,et al. Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.
[21] W. Weiss,et al. RNA interference against a glioma-derived allele of EGFR induces blockade at G2M , 2005, Oncogene.
[22] A. Scott,et al. The tumor-specific de2–7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR , 2004, Oncogene.
[23] P. Kleihues,et al. Predominant Expression of Mutant EGFR (EGFRvIII) is Rare in Primary Glioblastomas , 2004, Brain pathology.
[24] K. Aldape,et al. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR , 2004, Genes, chromosomes & cancer.
[25] Kenji Tada,et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.
[26] Huang Shao,et al. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. , 2003, Cancer research.
[27] Peter G. Schultz,et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase , 2000, Nature.
[28] A. Bishayee,et al. Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c-terminal tail. , 1999, Molecular biology of the cell.
[29] H. Wiley,et al. The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.
[30] J. Darnell,et al. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.
[31] P. Humphrey,et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[32] C. James,et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[33] W. Cavenee,et al. Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma , 2006, Brain Tumor Pathology.